138 related articles for article (PubMed ID: 38523872)
1. Late-Stage Ovarian Cancer With Systemic Multiple Metastases Shows Marked Shrinkage Using a Combination of Wilms' Tumor Antigen 1 (WT1) Dendritic Cell Vaccine, Natural Killer (NK) Cell Therapy, and Nivolumab.
Nagai H; Karube R
Cureus; 2024 Mar; 16(3):e56685. PubMed ID: 38523872
[TBL] [Abstract][Full Text] [Related]
2. Delayed-Type Hypersensitivity: An Excellent Indicator of Anti-tumor Immunity With Wilms' Tumor 1 (WT1) Dendritic Cell Vaccine Therapy.
Nagai H; Karube R
Cureus; 2023 Nov; 15(11):e49221. PubMed ID: 38143707
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.
Van Genechten T; De Laere M; Van den Bossche J; Stein B; De Rycke K; Deschepper C; Hazes K; Peeters R; Couttenye MM; Van De Walle K; Roelant E; Maes S; Vanden Bossche S; Dekeyzer S; Huizing M; Caluwaert K; Nijs G; Cools N; Verlooy J; Norga K; Verhulst S; Anguille S; Berneman Z; Lion E
BMJ Open; 2024 Mar; 14(3):e077613. PubMed ID: 38503417
[TBL] [Abstract][Full Text] [Related]
5. Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.
Smits EL; Stein B; Nijs G; Lion E; Van Tendeloo VF; Willemen Y; Anguille S; Berneman ZN
Methods Mol Biol; 2016; 1393():27-35. PubMed ID: 27033213
[TBL] [Abstract][Full Text] [Related]
6. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer.
Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
[TBL] [Abstract][Full Text] [Related]
8. Autologous Immune Enhancement Therapy for Cancer - Our experience since 2004.
Terunuma H
J Stem Cells Regen Med; 2012; 8(3):205-6. PubMed ID: 24693200
[TBL] [Abstract][Full Text] [Related]
9. Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1.
Ito Z; Kan S; Bito T; Horiuchi S; Akasu T; Yoshida S; Kajihara M; Hokari A; Saruta M; Yoshida N; Kobayashi M; Ohkusa T; Shimodaira S; Okamoto M; Sugiyama H; Koido S
Oncology; 2019; 97(3):135-148. PubMed ID: 31216557
[TBL] [Abstract][Full Text] [Related]
10. WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Yanagisawa R; Koizumi T; Koya T; Sano K; Koido S; Nagai K; Kobayashi M; Okamoto M; Sugiyama H; Shimodaira S
Anticancer Res; 2018 Apr; 38(4):2217-2225. PubMed ID: 29599342
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.
Ogasawara M; Miyashita M; Yamagishi Y; Ota S
Ther Apher Dial; 2019 Jun; 23(3):279-288. PubMed ID: 31033141
[TBL] [Abstract][Full Text] [Related]
12. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor 1 -targeting cancer vaccine: Recent advancements and future perspectives.
Ogasawara M
Hum Vaccin Immunother; 2024 Dec; 20(1):2296735. PubMed ID: 38148629
[TBL] [Abstract][Full Text] [Related]
14. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the efficacy and feasibility of combined therapy of PD-L1-enhanced exogenous peripatetic adoptive natural killer (NK) cells in combination with antiangiogenic targeted therapy in the treatment of extensive-stage small cell lung cancer.
Wang Z; Zhang R; Cao Y; Chen Y; Huang S; Luo Y
Thorac Cancer; 2023 Oct; 14(28):2877-2885. PubMed ID: 37596831
[TBL] [Abstract][Full Text] [Related]
16. NK cell-based therapeutics for lung cancer.
Pockley AG; Vaupel P; Multhoff G
Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156
[No Abstract] [Full Text] [Related]
17. WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y; Tsuboi A; Fujiki F; Li Z; Nakajima H; Hosen N; Shirakata T; Nishida S; Oji Y; Kawase I; Sugiyama H
Anticancer Agents Med Chem; 2009 Sep; 9(7):787-97. PubMed ID: 19538172
[TBL] [Abstract][Full Text] [Related]
18. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation.
Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S
Front Immunol; 2020; 11():559152. PubMed ID: 33101274
[TBL] [Abstract][Full Text] [Related]
19. Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies.
Coosemans A; Vergote I; Van Gool SW
Expert Rev Clin Immunol; 2014 Jun; 10(6):705-11. PubMed ID: 24784346
[TBL] [Abstract][Full Text] [Related]
20. Wilms' tumor 1 antigen immunoreactivity in epithelial ovarian cancer - diagnostic and prognostic value.
Zarychta E; Lepinay K; Szubert S; Jozwicki J; Misiak J; Brozyna AA; Kosinska-Kaczynska K; Lewandowska A; Malicka E; Makarewicz A; Rhone P; Jozwicki W
Folia Histochem Cytobiol; 2020; 58(3):198-207. PubMed ID: 32960974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
